Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

Share Price is delayed by 15 minutes
Get Live Data
13.50    0.00 (0.00%)
Bid:
13.25
Ask:
13.75
Spread: 0.50 (3.774%)
Market Cap: £65.58m
CREO Live PriceLast checked at - London Stock Exchange

Intraday Creo Medical Share Chart

Treasury Building Refinance

4 Aug 2009 07:00

RNS Number : 7945W
China Real Estate Opportunities PLC
04 August 2009
 



4 August 2009

China Real Estate Opportunities plc

Treasury Building Refinance

China Real Estate Opportunities plc ("CREO" or the "Company") is pleased to announce that terms have been agreed and credit approval received for a multi-currency five year loan facility equivalent to ₤26.6 million (based on current exchange rates) with the Industrial and Commercial Bank of China (ICBC). 

This facility will refinance the existing 18.8 million and RMB97 million loan CREO has with Credit Suisse in regard to the Treasury Building Shanghai which expires in March 2010. It is expected that this transaction will be completed by October 2009. Under the approved terms, CREO will benefit from approximately ₤2 million of increased liquidity, subject to the exchange rates prevailing at the date of the refinance, as the principal amount of the ICBC facility exceeds the existing Credit Suisse loan. In addition, the interest cost on this loan facility will be reduced by approximately ₤200,000 per annum, representing a 15% saving, based on the current 3 year London Interbank Offer Rate (LIBOR), when compared to the terms of the current loan.

Ray Horney, CREO Chairman commented, "I am most encouraged that credit approval has been received for the refinancing of the Treasury Building well ahead of the expiry of the current loan, as this provides confidence that progress can be made in relation to CREO's later refinancings.

 

The Company is developing strong relationships with Chinese banks and the Company's ability to secure additional funding and to extend the term of the debt facility further demonstrates the high quality, resilient nature of the Company's assets"

Contact:

CREO

Ray Horney, Chairman

Tel: + 44 (0) 1273 775 225 

Sarah Moriarty, Investor Relations

Tel: + 353 1 618 9455

Matrix Corporate Capital LLP

Paul Fincham, Rob Naylor

Tel: + 44 (0) 20 3206 7000

Davy

Des Carville

Tel: +353 1 679 6363

Bankside Consultants 

Simon Rothschild, Oliver Winters 

Tel: 44 (0) 20 7367 8888

Murray Consultants 

Ed Micheau

Tel: + 353 1 498 0300

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEXLFBKVBXBBE
Date   Source Headline
23rd Jun 20267:00 amRNSAppointment of Nominated Adviser /Corporate Broker
4th Jun 20267:00 amRNSPosting of 2025 Annual Report and Notice of AGM
28th May 20262:35 pmRNSHolding(s) in Company
22nd May 202610:11 amRNSResult of Placing
22nd May 20267:02 amRNSProposed Placing to raise approximately £5.5m
22nd May 20267:01 amRNSFY25 Final Results
22nd May 20267:00 amRNSProposed Sale of 49% Interest in Creo Medical SL
7th May 20267:00 amRNS-RMicroBlate™ Fine commercial update
5th May 20267:00 amRNS-RSpydrBlade™ Flex used in novel BEAM procedures
30th Apr 20267:00 amRNS-RKOL presentations on Creo Core Products at DDW
29th Apr 20267:00 amRNS-RUK private hospital use Speedboat for cancer case
22nd Apr 20267:00 amRNSPositive Q1 trading update
16th Apr 20267:00 amRNSDisposal and outsourcing of manufacturing
24th Feb 20267:00 amRNSAppointment of Joint Corporate Broker
20th Jan 20267:00 amRNSFY25 Trading Update
14th Jan 20267:00 amRNSAward of Shares under Share Incentive Plan
27th Oct 20257:00 amRNSNotice of Capital Markets Day
7th Oct 202511:37 amRNSCapital Markets Day update
22nd Sep 20257:00 amRNSUnaudited results for the six months ended 30 June
12th Sep 20253:14 pmRNSHolding(s) in Company
11th Sep 20257:00 amRNSNotice of Results
12th Aug 20254:56 pmRNSDirector/PDMR Share Dealing
4th Aug 20257:00 amRNS-RSpeedboat® patient testimonial
24th Jul 20257:00 amRNSAward of Shares under SIP and Director Dealings
21st Jul 20257:00 amRNSH1’25 Trading Update
10th Jul 20257:00 amRNS-RMicroBlate™ Flex begins lung tumour clinical study
9th Jul 20259:41 amRNSPDMR Options Revision
30th Jun 20257:00 amRNSChange of Nominated Adviser
26th Jun 202511:08 amRNSResult of AGM
26th Jun 20257:00 amRNSAGM Statement and Directorate Changes
11th Jun 20257:00 amRNS-RU.S. FDA clearance for SpydrBlade™ Flex
2nd Jun 20257:00 amRNSDirector/PDMR Shareholding
30th May 20257:00 amRNSPosting of AR&R and Notice of AGM
28th May 20257:00 amRNSUS Reimbursement milestone for Speedboat procedure
27th May 202512:48 pmRNSHolding(s) in Company
23rd May 20254:25 pmRNSHolding(s) in Company
22nd May 20257:00 amRNSDirectorate changes
19th May 20257:00 amRNSFinal Results
6th May 20257:00 amRNSNotice of investor presentations
15th Apr 20252:00 pmRNSNotice of Results
1st Apr 20259:34 amRNSHolding(s) in Company
31st Mar 202512:17 pmRNSHolding(s) in Company
26th Mar 20257:00 amRNSGrant of Options
20th Mar 20257:00 amRNS-RUK & EU Commercial launch of SpydrBlade™ Flex
6th Mar 20257:00 amRNSAppointment of Nominated Adviser and sole Broker
17th Feb 20257:00 amRNSFY24 Trading Update
12th Feb 202511:00 amRNSCompletion of sale of 51% interest in subsidiary
6th Feb 20259:00 amRNS-RFirst Welsh adopter of Speedboat® technology
3rd Feb 20253:00 pmRNSTotal Voting Rights
21st Jan 20257:00 amRNSAward of Shares under Share Incentive Plan

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.